Charles River Laboratories (CRL) financials
Charles River Laboratories revenue and earnings by year
Charles River Laboratories's revenue was $4.02 billion in the fiscal year to December 27, 2025, down 0.9% from the year before. Net income was -$144 million, -3.6% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 10.2% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.02 | 4.05 | 4.13 | 3.98 | 3.54 | 2.92 | 2.62 | 2.27 | 1.86 | 1.68 |
| Revenue growth | -0.9% | -1.9% | 3.9% | 12.3% | 21.1% | 11.5% | 15.7% | 22.0% | 10.5% | — |
| Gross profit | 1.32 | 1.33 | 1.50 | 1.46 | 1.33 | 1.07 | 0.96 | 0.84 | 0.70 | 0.64 |
| Gross margin | 33.0% | 32.9% | 36.4% | 36.8% | 37.7% | 36.7% | 36.6% | 37.1% | 37.7% | 38.3% |
| Operating income | 0.03 | 0.23 | 0.62 | 0.65 | 0.59 | 0.43 | 0.35 | 0.33 | 0.29 | 0.24 |
| Operating margin | 0.6% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% |
| Net income | -0.14 | 0.02 | 0.47 | 0.49 | 0.39 | 0.36 | 0.25 | 0.23 | 0.12 | 0.15 |
| Net margin | -3.6% | 0.5% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% |
| Diluted EPS | -$2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.06 | $4.61 | $2.54 | $3.23 |
| Free cash flow | 0.52 | 0.50 | 0.37 | 0.29 | 0.53 | 0.38 | 0.34 | 0.30 | 0.24 | 0.26 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open CRL in Markets.
See also: CRL valuation and P/E history · CRL returns
No forecast, no recommendation. This page describes Charles River Laboratories from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.